UDP glycosyltransferase family 3 member A2Genealiases: []
Q-omics provides the consensus-scored UGT3A2 profile across patient tissues and cancer cell-line models. UGT3A2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, UGT3A2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, UGT3A2 RNA expression shows 12,922 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KICH, and THYM as cancer lineages where UGT3A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGT3A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGT3A2 survival associations across molecular data types. UGT3A2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGT3A2 RNA expression–survival associations across cancer types. High UGT3A2 expression shows unfavorable associations in UCEC, but favorable associations in BRCA, SKCM, BLCA, LAML and PRAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for UGT3A2 RNA expression.
This table summarizes UGT3A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UGT3A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGT3A2 shows lower tumor expression in KICH, KIRC and COAD and higher tumor expression in THCA, LIHC and LUSC. The KICH box plot shows higher UGT3A2 RNA expression in normal versus tumor tissue (log2 FC = −1.824, t-test p < 0.001).
This table shows molecular features associated with UGT3A2 in patient tissues and cancer cell lines. In patient samples, UGT3A2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UGT3A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
